SE1660037T5 - - Google Patents

Info

Publication number
SE1660037T5
SE1660037T5 SE04779411T SE04779411T SE1660037T5 SE 1660037 T5 SE1660037 T5 SE 1660037T5 SE 04779411 T SE04779411 T SE 04779411T SE 04779411 T SE04779411 T SE 04779411T SE 1660037 T5 SE1660037 T5 SE 1660037T5
Authority
SE
Sweden
Prior art keywords
extended release
injection
aripiprazole
complexities
polylactide
Prior art date
Application number
SE04779411T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34116189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE1660037(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of SE1660037T5 publication Critical patent/SE1660037T5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE04779411T 2003-08-06 2004-07-29 SE1660037T5 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/635,221 US20050032811A1 (en) 2003-08-06 2003-08-06 Methods for administering aripiprazole

Publications (1)

Publication Number Publication Date
SE1660037T5 true SE1660037T5 (xx) 2015-09-15

Family

ID=34116189

Family Applications (1)

Application Number Title Priority Date Filing Date
SE04779411T SE1660037T5 (xx) 2003-08-06 2004-07-29

Country Status (22)

Country Link
US (9) US20050032811A1 (xx)
EP (2) EP2340810A1 (xx)
JP (3) JP5300194B2 (xx)
CN (2) CN1845721A (xx)
AT (1) ATE522200T1 (xx)
AU (1) AU2004264886C1 (xx)
CA (1) CA2534997C (xx)
CY (1) CY1111874T1 (xx)
DK (1) DK1660037T3 (xx)
ES (1) ES2369893T3 (xx)
HK (1) HK1091725A1 (xx)
HR (1) HRP20110646T1 (xx)
IL (1) IL173441A (xx)
MX (1) MXPA06001350A (xx)
NO (1) NO339816B1 (xx)
NZ (1) NZ545037A (xx)
PL (1) PL1660037T3 (xx)
PT (1) PT1660037E (xx)
SE (1) SE1660037T5 (xx)
SI (1) SI1660037T1 (xx)
WO (1) WO2005016262A2 (xx)
ZA (1) ZA200601385B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
EP2279727A3 (en) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
ES2437581T3 (es) * 2005-11-17 2014-01-13 Zogenix, Inc. Suministro de formulaciones viscosas por inyección sin aguja
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
SG182232A1 (en) * 2007-06-25 2012-07-30 Otsuka Pharma Co Ltd Microspheres having core/shell structure
UA97286C2 (ru) * 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
PT2445502T (pt) * 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
AR083884A1 (es) * 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
RU2627469C2 (ru) * 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
EP2790734B1 (en) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
NZ748572A (en) 2012-09-19 2020-07-31 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN105078898B (zh) * 2014-05-22 2018-08-28 上海现代药物制剂工程研究中心有限公司 阿立哌唑长效缓释微粒注射剂及其制备方法
SI3508196T1 (sl) * 2014-08-18 2021-12-31 Alkermes Pharma Ireland Limited, Sestavki aripiprazolnega predzdravila
EP3185867B1 (en) 2014-08-25 2021-01-13 Alkermes Pharma Ireland Limited Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
WO2021199076A1 (en) 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
AU2021245713A1 (en) 2020-04-01 2022-12-01 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
CN115212174B (zh) * 2022-07-18 2024-02-20 辉粒药业(苏州)有限公司 一种载阿立哌唑长效缓释微球及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5832899A (ja) * 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001293048A1 (en) * 2000-09-26 2002-04-08 The Johns Hopkins University Antiviral compositions and methods of use
DE10048868A1 (de) * 2000-10-02 2002-04-11 Basf Ag Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
JP2002191256A (ja) 2000-12-26 2002-07-09 Yoshikatsu Nakajima 水 槽
MXPA03011538A (es) * 2001-06-14 2004-03-09 Otsuka Pharma Co Ltd Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method

Also Published As

Publication number Publication date
IL173441A0 (en) 2006-06-11
US8338427B2 (en) 2012-12-25
JP2014001250A (ja) 2014-01-09
JP5300194B2 (ja) 2013-09-25
ES2369893T3 (es) 2011-12-07
US20090143403A1 (en) 2009-06-04
PL1660037T3 (pl) 2012-03-30
CY1111874T1 (el) 2015-11-04
US20050032811A1 (en) 2005-02-10
NZ545037A (en) 2008-10-31
NO20060638L (no) 2006-04-26
JP2010248258A (ja) 2010-11-04
JP2007501236A (ja) 2007-01-25
CA2534997C (en) 2011-11-01
AU2004264886C1 (en) 2021-06-03
US20180169005A1 (en) 2018-06-21
NO339816B1 (no) 2017-02-06
JP5764634B2 (ja) 2015-08-19
ATE522200T1 (de) 2011-09-15
US8338428B2 (en) 2012-12-25
WO2005016262A3 (en) 2005-09-09
US20140275109A1 (en) 2014-09-18
HRP20110646T1 (hr) 2011-12-31
HK1091725A1 (en) 2007-01-26
CN102133171A (zh) 2011-07-27
US20210346282A1 (en) 2021-11-11
PT1660037E (pt) 2011-10-24
US20230218506A1 (en) 2023-07-13
IL173441A (en) 2013-04-30
US20120289516A1 (en) 2012-11-15
DK1660037T3 (da) 2011-12-12
EP1660037A4 (en) 2008-09-24
EP2340810A1 (en) 2011-07-06
EP1660037A2 (en) 2006-05-31
MXPA06001350A (es) 2006-08-23
SI1660037T1 (sl) 2012-05-31
AU2004264886A1 (en) 2005-02-24
WO2005016262A2 (en) 2005-02-24
CN1845721A (zh) 2006-10-11
ZA200601385B (en) 2007-02-28
US20130090343A1 (en) 2013-04-11
JP5453194B2 (ja) 2014-03-26
AU2004264886B2 (en) 2007-06-07
US20190231679A1 (en) 2019-08-01
CA2534997A1 (en) 2005-02-24
US8759351B2 (en) 2014-06-24
EP1660037B1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
SE1660037T5 (xx)
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY151468A (en) Controlled release solid preparation
AP2001002264A0 (en) Sustained release formulations for growth hormone secretagogues.
WO2006002365A3 (en) Microparticles with high loadings of a bioactive agent
BR0212475A (pt) Composições farmacêuticas
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
NZ594618A (en) Transdermal pharmaceutical preparations
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
HK1119596A1 (en) Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases
IL157955A0 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
ATE334658T1 (de) Arzneimittel zur verabreichung an schleimhäute
WO2005062874A3 (en) Compounds and compositions for delivering active agents
WO2004069228A3 (en) Sustained release formulations of venlafaxine
MD20040296A (ro) Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ